America’s Health in China’s Hands
Amoxicillin might seem like a routine, easy-to-get antibiotic—but its production highlights a hidden reliance on China. A new analysis published Wednesday found that nearly 700 U.S. medicines contain at least one chemical sourced almost entirely from China.
According to The New York Times, drug manufacturing involves multiple steps. It starts with foundational chemicals known as Key Starting Materials (KSMs), which are then turned into active ingredients and finally combined into the finished drug. The study, conducted by nonprofit US Pharmacopeia, shows that the KSM stage is heavily dependent on Chinese suppliers.
These chemicals aren’t produced in the U.S. largely because the process is considered “dirty,” according to the Times. China offers cheaper labor and looser environmental regulations, making it the dominant source. This reliance affects not only amoxicillin but also generic drugs for heart conditions, cancer, HIV, and even everyday allergy medications.
The analysis takes a closer look at amoxicillin. While the U.S. supply chain appears diverse—with manufacturers in India, China, Austria, Spain, Italy, Singapore, Canada, Jordan, Slovenia, and the U.S.—the drug’s production ultimately depends on four KSMs, all nearly entirely produced in China. One of these KSMs is also critical for other antibiotics, including ampicillin, dicloxacillin, nafcillin, oxacillin, and piperacillin. The study concludes that even a seemingly broad manufacturing network provides little protection when all production relies on the same upstream source.
About Post Author
